TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02029872
Drug: Mupirocin calcium 2 % ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal mupirocin calcium 2% ointment
Study: NCT00964886
Drug: desipramine hydrochloride
Normalized name: Desipramine Hydrochloride
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
Study: NCT00964886
Drug: benztropine mesylate 0.125 mg daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: benztropine mesylate is a placebo, some of whose side effects mimic those of experimental intervention, desipramine hydrochloride
Study: NCT02449369
Drug: Postop oral oxycodone & acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02223351
Drug: ASP2151
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02084511
Drug: Placebo to BI 1026706 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to BI 1026706 solution
Study: NCT02084511
Drug: Placebo to BI 1026706 tablet
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to BI 1026706 tablet
Study: NCT02084511
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib capsule
Study: NCT03427710
Drug: CiVi007
Approvals — FDA: no, EMA: no, PMDA: no
Description: cholesterol lowering drug
Study: NCT00246584
Drug: SPP100
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02449369
Drug: Postop acetaminophen IV
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00366080
Drug: GSK189254
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00887484
Drug: BENZOYL PEROXIDE/ CLINDAMYCIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
Study: NCT01939314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
Study: NCT01859988
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01379378
Drug: Contigen
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5-10 cc
Study: NCT01072630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo, also in tablet form taken orally, once daily in the morning.
Study: NCT00400725
Drug: Clobex® Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobex® Shampoo 0.05 % (W/W) topically to scalp for 4 weeks.
Study: NCT00400725
Drug: Clobex® Vehicle Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobex® Vehicle Shampoo 0.05 % (W/W) topically to scalp up to 6 months.
Study: NCT00400725
Drug: Clobex® Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobex® Shampoo 0.05% (W/W) topically to scalp up to 6 months.
Study: NCT03914638
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, three times daily
Study: NCT02755818
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements
Study: NCT00001145
Drug: Bacteriophage
Normalized name: bacteriophages
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00225823
Drug: GW685698X
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01908192
Drug: NaBen®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Study Treatment is NaBen®, which will look, and will be packaged and maintained exactly the same way as the Control Treatment (Placebo).
Study: NCT01908192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The ingredients in the Control Treatment are exactly the same as in the Study Treatment, except without the primary active ingredient.
Study: NCT04411160
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nitric oxide stared by 50 parts/billion(ppb) as starting dose titrated according to patient's saturation reaching to 90 ppb as a maximum dose
Study: NCT04479267
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04479267
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04479267
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02217475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally once daily and taken every morning with food.
Study: NCT01044017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT01044017
Drug: RO4998452
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral doses
Study: NCT00728897
Drug: GSK598809 new formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK598809 new formulation will be available as an immediate release capsule with a single dose of 100 milligrams, administered orally with 240 milliliters of water.
Study: NCT00728897
Drug: GSK598809 old formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK598809 old formulation will be available as an immediate release capsule with a single dose of 25 milligrams, administered orally with 240 milliliters of water.
Study: NCT02141022
Drug: Gileyna
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02703259
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02703259
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00130494
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02311231
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with unfractionated Heparin 5000 IU/ml i.v. ,Leo Pharma, Sweden, (the control group). Heparin in the control group is administered as an intravenous or intra-arterial bolus according to local practice. A dose of 70-100 U/kg is recommended
Study: NCT04308863
Drug: Chitosan scaffold/ MTA pulp dressing material
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan 3-D porous scaffold will be prepared. The chitosan scaffolds will be examined with the Scanning electron microscopy (SEM) to analyze the surface of the chitosan scaffolds. The scaffolds will be sterilized by Ethylene oxide and stored until further use. A piece of 2-mm thick chitosan scaffold will be gently placed onto the pulp chamber floor and covering the canal orifices, and then a 2-3 mm thick layer of fast setting EndoCem Zr MTA will be applied onto the chitosan scaffold and will be gently condensed with moistened cotton pellet to attain adequate thickness which will be confirmed radiographically. MTA will be allowed to set for 4-5 mins.
Study: NCT04308863
Drug: MTA pulp dressing material
Normalized name: acai fruit pulp
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTA will be gently placed over the fresh pulp wound using an MTA carrier to a thickness of 2-3 mm. It will be condensed lightly with moistened cotton pellet to attain adequate thickness and confirmed radiographically. MTA will be allowed to set for 4-5 mins.
Study: NCT02485067
Drug: Placebo(For THVD-201)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02485067
Drug: Placebo(For Detrusitol 2mg tablet)
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00759824
Drug: Adriamycin, cyclophosphamide, vindesine, valproic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin 45 mg/m² day 1 IV Cyclophosphamide 1 g/m² day 1 IV Vindesine 3 mg/m² day 1 IV Valproic acid 20-30 mg/kg/day from day -7 until the end of treatment, orally
Study: NCT00890643
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02892942
Drug: Gonal-F®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 to 450 IU/d; from day 2 of menstrual cycle onward
Study: NCT02892942
Drug: Cetrotide®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/day, starting on day 6 of Gonal-F®.
Study: NCT02892942
Drug: Cetrotide®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/day (6 ampoules of 0.25 mg), starting on day 1 (S1) of Gonal-F® treatment until dhCG
Study: NCT00625547
Drug: levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa oral capsules: 25 mg twice daily on Days 1 to 3, 50 mg twice daily on Days 4 to 7, 100 mg twice daily on Days 8 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 150 mg twice daily if patient experienced insufficient efficacy without impairing adverse events
Study: NCT02818725
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: METHOTREXATE: 30 mg/m² on day 1 VINBLASTINE: 3 mg/m² on day 2 DOXORUBICIN: 30 mg/m² on day 2 CISPLATIN: 70 mg/m² on day 2
Study: NCT02605655
Drug: AMP-1915
Approvals — FDA: no, EMA: no, PMDA: no
Description: A traditional Chinese Formula extract from Astragalus, Radix Puerariae and Cortex Mori is mixed into instant noodles. Patients are treated with AMP-1915 as meal.
Study: NCT01992601
Drug: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period.~For separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period.
Study: NCT00313625
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01604889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00289861
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01060098
Drug: anti-TNF therapy (etanercept or adalimumab)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological DMARD
Study: NCT01466101
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo
Study: NCT01376232
Drug: GSK1278863 + food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Fat meal + 100 mg GSK1278863
Study: NCT03428282
Drug: Anesthesia
Normalized name: anesthesia tray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia will be obtained by injecting the drug into the oral mucosa before performing the dental treatment.
Study: NCT01269515
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg QD
Study: NCT01719419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with placebo.
Study: NCT02689856
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream alone
Study: NCT02689856
Drug: Hydrocortisone acetate
Normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: hydrocortisone alone
Study: NCT03085654
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal administration of placebo 24 international units per dose.
Study: NCT01942590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00720590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of placebo for 4 weeks
Study: NCT03767582
Drug: CCR2/CCR5 dual antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCR2/CCR5 dual antagonist (150 mg capsules) will be administered orally twice a day, on days 1-28 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery CCR2/CCR5 dual antagonist will be given daily on cycles 2-5. Cycles are 4 weeks long.
Study: NCT00144599
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00483535
Drug: GW273225
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW273225 will be available as 25 milligram tablets.
Study: NCT02230891
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure
Study: NCT01259947
Drug: Lippia alba (Mill.) N. E. Brown ethanolic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 drops per kilogram per day, PO, twice a day
Study: NCT02259920
Drug: KUC 7483 CL, immediate release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00513019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily
Study: NCT00453791
Drug: GW805858
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.
Study: NCT00453791
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo MDI will be given to the subjects.
Study: NCT00467350
Drug: milk and molasses enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance
Study: NCT03279809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case with placebo medication for 6 months after stenting
Study: NCT02531295
Drug: Euphorbia kansui extract powder prepared as tea
Normalized name: Euphorbia kansui whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily
Study: NCT04554043
Drug: SHR7280
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment
Study: NCT04554043
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: blank control
Study: NCT02104843
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01728311
Drug: BAY1082439
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg.
Study: NCT01887886
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV every 3 weeks
Study: NCT02739555
Drug: Acide Zoledronique
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04879953
Drug: Systemic chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy
Study: NCT03130153
Drug: Aspirin Powder
Normalized name: ASPIRIN 500 mg in 1 g ORAL POWDER [Aspirin Powder]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin powder to be dissolved in water and to be used as mouthwash twice daily for 7 days after tooth extraction.
Study: NCT03130153
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline to be used as mouthwash twice daily for 7 days after tooth extraction among non-hypertensive subjects.
Study: NCT04268927
Drug: GnRH ant
Normalized name: wood ant preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration .
Study: NCT00622037
Drug: PEG-400 based artificial tear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
Study: NCT04301856
Drug: CFTR Modulators
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFTR modulators as recommended in routine care by the french health authorities
Study: NCT04953195
Drug: Levothyroxine Sodium Tablets
Normalized name: Levothyroxine Sodium Tablets
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine Sodium(50ug/Tablets,dosage form 25ug,once a day) was administered to patients with autoimmune thyroiditis with mild subclinical hypothyroidism,
Study: NCT00490230
Drug: WR 279396
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01526408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).
Study: NCT02766465
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A:~Methotrexate will be administered intravenously on day+1 at 15mg/m\^2, day+3 at 10mg/m\^2, day+6 at 10mg/m\^2, and day+11 at 10mg/m\^2.~C:~Methotrexate IV 7.5 mg/m2 dose will be given on Days +1, 3, +6 following transplant
Study: NCT02549014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose for each period administered as oral placebo tablets matching active MK-1064 tablets
Study: NCT02402621
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl with antiemetic drug
Study: NCT01646567
Drug: Placebo to SHP-141C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Topical Cream
Study: NCT04697940
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3.
Study: NCT01361191
Drug: R-MEGACHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: * If PET + after third cycle: 2 cycles of R-IFE followed by PBSCT~* If PET - after third cycle: 3 additional cycles of R-MegaCHOP - R-MegaCHOP: cycles every 21 days RITUXIMAB Dosage: 375mg/m2, IV, day 1 CICLOPHOSPHAMIDE Dosage: 1500 mg/m2, IV, day 1 DOXORUBICIN Dosage: 65 mg/m2, IV, day 1 VINCRISTIN: Dosage 1.4 mg/m2 (max. 2.0 mg/m2, IV, day 1 PREDNISONE Dosage: 60 mg/m2, IV, day 1-5~R-IFE: 2 cycles every 21 days:~IFOSFAMIDE Dosage: continuous perfusion of 10 gr/m2/iv during 72 hours. Therefore, 3.33 gr/m2/corporal weight 24 hours day +1, +2 and +3.~ETOPOSIDE Dosage: total 900 mg/m2, IV, which is 150 mg/m2 during 12 hours (days +1, +2 and +3).
Study: NCT00835900
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01719705
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ninety minutes before surgery, the parturients receive two identical placebo capsules
Study: NCT03981861
Drug: Metformin and Spironolactone
Normalized name: metformin and ertugliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Metformin tablet (500 mg/tablet) twice daily for 6 months. Oral Spironolactone tablet (50 mg/tablet) once daily for 6 months.
Study: NCT03249753
Drug: SPH3127 200mg Panel A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.
Study: NCT03985371
Drug: EDTA Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in the Band Keratopathy affected eye only, two times per day for six months.
Study: NCT03249753
Drug: SPH3127 200mg Panel B
Normalized name: benzocaine 200 MG/ML [Zilactin B]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.
Study: NCT02740712
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg (4 x 50mg) Tablet
Study: NCT01412151
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose
Study: NCT01081626
Drug: Recombinant FSH (follitropin alpha)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A starting dose of 75 IU and a first adjustment on Day 14 or Day 7 of stimulation in Group I and II respectively, if no ovarian response is observed.
Study: NCT00976872
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
Study: NCT00215137
Drug: Placebo ( sugar pill)
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator in double.blind phase.
Study: NCT04187807
Drug: Melatonin 5 mg
Normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo
Study: NCT02158052
Drug: Bone marrow transplant from a related donor
Normalized name: Sus scrofa bone marrow preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor bone marrow (\> 2 x 10e8 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed.
Study: NCT01023607
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin,10mg/day
Study: NCT00124787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PO q 6 hours x 4 doses
Study: NCT01775475
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01775475
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01775475
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO